Some sulfonamides as aldose reductase inhibitors: therapeutic approach in diabetes. (4th July 2022)

• Record Type: Journal Article
• Authors: Demir, Yeliz; Köksal, Zeynep
• Is Part Of: Archives of physiology and biochemistry. Volume 128:Number 4(2022)
• Page Start: 979
• Page End: 984
• Publication Date: 2022-07-04
• Subjects: Enzyme purification -- aldose reductase -- oxidative stress -- enzyme inhibition -- sulfonamides; Physiology -- Periodicals; Biochemistry -- Periodicals; Biophysics -- Periodicals; Biochemistry; Physiology; 571
• DOI: 10.1080/13813455.2020.1742166
• Languages: English
• ISSNs: 1381-3455

Abstract

Abstract: In this study, aldose reductase (AR) was purified from sheep kidney using chromatographic methods and examined the interactions between some sulfonamides and the enzyme. According to results, sulfonamides display effective inhibitor features for sheep kidney AR with IC50 values in the range of 37.27–87.65 μM and K i s in the range of 25.72 ± 6.45 to 73.56 ± 17.49 μM. The sulfonamides displayed different inhibition mechanisms. It was found that studied all compounds displayed non-competitive inhibition type except for 5-chlorothiophene-2-sulfonamide (1). It showed competitive inhibition. Among these compounds, 2, 5-dichlorothiophene-3-sulfonamide compound (2) was showed the most potent AR inhibitor ( K i : 25.72 ± 6.45). These compounds may be useful in the treatment of diabetic complications.